reason report
restructur help number eye upcom
bottom line stock trade today close investor
respond posit new restructur effort cost
save off-set lower aristada sale
guidanc good news realli one-tim
rebas spend infrastructur overal stock
pressur recent investor struggl get comfort
focu signific invest oncolog well
prospect manag commentari
confer call probabl wont resolv issu yet
signific wait see attitud stock
upcom data import
chang pt mp rate
chang financi model includ adjust
expens restructur revis sale forc number
lower aristada peak sale manag indic
restructur plan elimin posit decreas
near-term hire appli cost-sav measur
result annual cost save save
sg appli estim
regard spend manag indic consensu spend
take restructur
effort new expens base would rang
middl rang
lower sale forc add rep push
hire base regulatori timelin nda file
regular review plu reschedul also
base manag commentari better leverag aristada
rep lower peak aristada sale estim
result chang model detail
increas ep forecast
highlight call regard key market product vivitrol
aristada vivitrol slower growth quarter sale yoy
driven unit growth manag note sequenti decreas
gross-to-net adjust medicaid util
favor impact sale vivitrol slightli higher
vs driven increas contribut
medicaid unit henc manag lower high end
guidanc rang
continu expect view state
vs state drive yoy unit growth aristada
sotp cash flow
discount rate
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
net sale increas yoy driven unit growth yoy total rx
data slow qoq growth yoy growth vs qoq
yoy basic unchang prior quarter
second quarter row manag lower
aristada sale guidanc
prior guidanc even expect
also year compani admit earli
expect aristada ambiti reiter
increas sale forc alpin data help drive futur
highlight call regard manag
indic track file nda dual
schizophrenia bipolar disord indic compani note
major chang sinc last quarter emphas
start discuss fda around year ago includ
pharmacokinet bridg data olanzapin bipolar indic
manag note would leverag aristada sale
forc thu would probabl need lower number new
sale rep new asset
highlight call regard manag
indic part reason restructur plan maintain
abil invest strongli pursu combin
tumor type efficaci data becom avail manag
confirm present data program societi
immunotherapi cancer meet
data patient primarili enrol pembrolizumab
unapprov tumor type across whole monotherapi dose
escal phase well trial progress poster
flexibl includ data updat manag caveat
probabl wont make howev also caveat sinc
expans cohort renal cell melanoma open recent
investor expect data patient addit
manag reiter compani still expect spend
 like
believ stop compani base mix efficaci data
opioid concern importantli neg feedback fda adcom
fda
believ expect high physician like
product believ reimburs difficult new brand without novel moa
dont agre bullish stanc investor base busi justifi
current valuat whole compani thu pipelin view free wildcard
pt base sotp analysi forecast cash flow
earlier-than-expect deterior royalti
flatten growth trajectori vivitrol aristada
lower royalti revenu due earlier-than-expect gener entri tecfidera
neg efficacy/safeti data
efficaci data monotherapi combin
pembrolizumab
schizophrenia
complet dose-escal stage monotherapi
combin pembrolizumab
initi dose-expans stage monotherapi
combin studi
head head
 incom statement million except per-shar profit acquir intang non-oper net incom net incom share basic ep basic share ep share ep compani report svb leerink llc estimatesco ep plc
sale ustot growth rate per rx price per rx average monthli growth rate growth rate total total growth per rx net per rx growth per rx net per rx growth net adjust per rx net growth rate growth rate alkerm plc
sale growth rate trx add uncaptur per rx gross per rx gross per rx gross per rx gross increas total trx total trx total trx total trx per rx gross per rx average monthli growth rate growth rate net per rx growth rate growth rate alkerm plc
million except per-shar royalti revenuesj partner long-act antipsychoticsinvega sustenna/xeplion/trinza/trevictau sustenna growth rate us sustenna royaltiesu trinza growth rate us trinza royaltiesu sustenna/trinza growth sustenna growth rate ou sustenna royalties trinza growth rate ou trinza royalties sustenna/trinza growth sustenna/trinza growth rate invega sustenna/trinza growth constau growth growth growth manufactur royalti rate sale royalti rate risperd consta partner growth alkerm plc
 balanc sheet million except per-shar asset receiv expens current plant asset tax stockhold equitycurr liabilitiesaccount payabl accru revenu debt current portion lt current liabilitieslong term revenu long long term non-curr equitycommon stock stock paid-in comprehens stockhold liabil stockhold compani report svb leerink llc estim plc
 statement million except per-shar oper activitiesnet compens long term incom oper asset liabil work use oper invest activitiescapit expendititur sale equipment/financi use invest financ activitieschang common stock tax benefit stock-bas purchas risperd consta note long-term debt capit leas use financ equival begin equival end compani report svb leerink llc estim plc
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori plc
leerink place outperform rate octob
creat bluematrix
pt base sotp analysi forecast cash flow discount rate
risk valuat
earlier-than-expect deterior royalti
flatten growth trajectori vivitrol aristada
lower royalti revenu due earlier-than-expect gener entri tecfidera
neg efficacy/safeti data
rate price target histori biogen inc
leerink place market perform rate februari
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach price earn price sale dcf price earn
approach appli current multipl controversi pipeline-driven larg cap biopharma compani
ep forecast produc one-year price target price sale approach
use current averag price sale similar larg cap biopharma compani transit legaci pipelin
product appli revenu forecast produc
price target lastli dcf take present valu forecast annual free cash flow
assum valu termin cash flow base termin growth rate discount
compani cost capit present valu averag approach current one-
year price target
risk valuat
risk view outlook valuat includ major chang price reimburs
coverag label compani exist treatment multipl sclerosi tysabri avonex plegridi tecfidera
success develop rapid market share gain competitor product class success
gener challeng tecfidera intellectu properti posit alter ahead expect risk
includ disappoint question result on-going trial import develop program
signific risk valuat disappoint file label launch aducanumab
compani singl import pipelin product opportun better perform
valu includ strong result midstag pipelin includ novel pain treatment vixotrigin anti-
lingo myelin restor product opicinumab success progress compani co-develop alzheim
diseas treatment eisai ban
rate price target histori johnson johnson
leerink place outperform rate januari
creat bluematrix
next month believ share trade price target price target appli
price-to-earnings multipl ep estim share current trade ep estim
large-cap med-tech group rang price target
assum see multipl expans line broader comp group compani manag
top-lin headwind continu drive oper leverag -- posit sustain
ep out-performance view total return capabl attract increasingli volatil stock market
environ like attract fund riskier area
risk valuat
risk includ failur success integr auri potenti futur acquisit failur resolv
outstand consum consent decre success re-launch product product recal failur
advanc late-stag pipelin success launch new product protract recoveri procedur volum
trend lack real macroeconom recoveri
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
